Rising Biosciences (Rising Biosciences) Accumulated Depreciation : $0.00 Mil (As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Rising Biosciences Accumulated Depreciation Historical Data

The historical data trend for Rising Biosciences's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Accumulated Depreciation Chart

Rising Biosciences Annual Data

Trend

Accumulated Depreciation

Rising Biosciences Quarterly Data

Accumulated Depreciation

Rising Biosciences Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Rising Biosciences Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Accumulated Depreciation

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.